LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | HG-6-64-01 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 1018 | 4405 | 0.2289 | -0.1232 |
MDA-MB-231 | HG-6-64-01 | 10 | uM | LJP6 | 72 | hr | 1235 | 234 | 4405 | 0.0524 | -0.6111 |
MDA-MB-231 | Neratinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4700 | 4660 | 1.0099 | 1.0111 |
MDA-MB-231 | Neratinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4531 | 4660 | 0.9743 | 0.9739 |
MDA-MB-231 | Neratinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 3537 | 4660 | 0.7596 | 0.7325 |
MDA-MB-231 | Neratinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 2421 | 4660 | 0.5183 | 0.4159 |
MDA-MB-231 | Neratinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1539 | 4660 | 0.3309 | 0.1218 |
MDA-MB-231 | Neratinib | 10 | uM | LJP5 | 72 | hr | 1235 | 797 | 4660 | 0.1734 | -0.2107 |
MDA-MB-231 | JW-7-24-1 | 0.04 | uM | LJP6 | 72 | hr | 1235 | 4157 | 4405 | 0.9428 | 0.9355 |
MDA-MB-231 | JW-7-24-1 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4098 | 4405 | 0.9292 | 0.9199 |
MDA-MB-231 | JW-7-24-1 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 3542 | 4405 | 0.8028 | 0.7723 |
MDA-MB-231 | JW-7-24-1 | 1.11 | uM | LJP6 | 72 | hr | 1235 | 2889 | 4405 | 0.6546 | 0.5850 |
MDA-MB-231 | JW-7-24-1 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 2617 | 4405 | 0.5934 | 0.5030 |
MDA-MB-231 | JW-7-24-1 | 10 | uM | LJP6 | 72 | hr | 1235 | 632 | 4405 | 0.1429 | -0.3106 |
MDA-MB-231 | Dasatinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 2691 | 4660 | 0.5783 | 0.5023 |
MDA-MB-231 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 807 | 4405 | 0.1832 | -0.2078 |
MDA-MB-231 | Dasatinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 1345 | 4660 | 0.2890 | 0.0451 |
MDA-MB-231 | Dasatinib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 801 | 4405 | 0.1820 | -0.2107 |
MDA-MB-231 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 790 | 4660 | 0.1696 | -0.2095 |
MDA-MB-231 | Dasatinib | 0.37 | uM | LJP6 | 72 | hr | 1235 | 771 | 4405 | 0.1752 | -0.2270 |
MDA-MB-231 | Dasatinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 653 | 4660 | 0.1398 | -0.2854 |
MDA-MB-231 | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 1235 | 661 | 4405 | 0.1498 | -0.2930 |
MDA-MB-231 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 671 | 4660 | 0.1440 | -0.2738 |
MDA-MB-231 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 627 | 4405 | 0.1421 | -0.3156 |
MDA-MB-231 | Dasatinib | 10 | uM | LJP5 | 72 | hr | 1235 | 638 | 4660 | 0.1362 | -0.2971 |